1.50
0.09 (6.38%)
0.09 (6.38%)
Upgrade to Real-Time
Afterhours (Closed)
| Volume | 1,716,675 |
|
|||||
| News | - | ||||||
| Day High | 1.48 | Low High |
|||||
| Day Low | 1.38 | ||||||
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Atossa Therapeutics Inc | ATOS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
 |
|
|---|---|---|---|---|
| 0.09 | 6.38% | 1.50 | 19:10:47 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.39 | 1.38 | 1.48 | 1.46 | 1.41 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 4,836 | 1,716,675 | $ 1.43 | $ 2,458,048 | - | 1.13 - 9.80 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:35:38 | 10 | $ 1.50 | USD |
Period:
Draw Mode:
Atossa Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 189.94M | 126.62M | 126.57M | $ - | $ - | -1.97 | -1.40 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | - | 0.40% |
Atossa Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ATOS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.56 | 1.62 | 1.38 | 1.49 | 1,854,152 | -0.06 | -3.85% |
| 1 Month | 1.90 | 1.97 | 1.38 | 1.68 | 2,888,875 | -0.40 | -21.05% |
| 3 Months | 2.7888 | 2.908 | 1.38 | 2.17 | 3,119,429 | -1.29 | -46.21% |
| 6 Months | 6.80 | 7.15 | 1.38 | 3.39 | 5,971,525 | -5.30 | -77.94% |
| 1 Year | 1.2066 | 9.80 | 1.13 | 3.76 | 13,323,092 | 0.2934 | 24.32% |
| 3 Years | 1.42 | 9.80 | 0.755 | 3.57 | 5,313,681 | 0.08 | 5.63% |
| 5 Years | 18.00 | 22.20 | 0.755 | 4.14 | 3,825,383 | -16.50 | -91.67% |
Atossa Therapeutics Description
| Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in the US. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use. |